{"0": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Council Directive\u00a090/385/EEC\u00a0(3) and Council Directive\u00a093/42/EEC\u00a0(4) constitute the Union regulatory framework for medical devices, other than in vitro diagnostic medical devices. However, a fundamental revision of those Directives is needed to establish a robust, transparent, predictable and sustainable regulatory framework for medical devices which ensures a high level of safety and health whilst supporting innovation."}, "1": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "This Regulation aims to ensure the smooth functioning of the internal market as regards medical devices, taking as a base a high level of protection of health for patients and users, and taking into account the small- and medium-sized enterprises that are active in this sector. At the same time, this Regulation sets high standards of quality and safety for medical devices in order to meet common safety concerns as regards such products. Both objectives are being pursued simultaneously and are inseparably linked whilst one not being secondary to the other. As regards Article\u00a0114 of the Treaty on the Functioning of the European Union (TFEU), this Regulation harmonises the rules for the placing on the market and putting into service of medical devices and their accessories on the Union market thus allowing them to benefit from the principle of free movement of goods. As regards Article\u00a0168(4)(c)\u00a0TFEU, this Regulation sets high standards of quality and safety for medical devices by ensuring, among other things, that data generated in clinical investigations are reliable and robust and that the safety of the subjects participating in a clinical investigation is protected."}, "2": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "This Regulation does not seek to harmonise rules relating to the further making available on the market of medical devices after they have already been put into service such as in the context of second-hand sales."}, "3": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Key elements of the existing regulatory approach, such as the supervision of notified bodies, conformity assessment procedures, clinical investigations and clinical evaluation, vigilance and market surveillance should be significantly reinforced, whilst provisions ensuring transparency and traceability regarding medical devices should be introduced, to improve health and safety."}, "4": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "To the extent possible, guidance developed for medical devices at international level, in particular in the context of the Global Harmonization Task Force (GHTF) and its follow-up initiative, the International Medical Devices Regulators Forum (IMDRF), should be taken into account to promote the global convergence of regulations which contributes to a high level of safety protection worldwide, and to facilitate trade, in particular in the provisions on Unique Device Identification, general safety and performance requirements, technical documentation, classification rules, conformity assessment procedures and clinical investigations."}, "5": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "For historical reasons, active implantable medical devices, covered by Directive\u00a090/385/EEC, and other medical devices, covered by Directive\u00a093/42/EEC, were regulated in two separate legal instruments. In the interest of simplification, both directives, which have been amended several times, should be replaced by a single legislative act applicable to all medical devices other than in vitro diagnostic medical devices."}, "6": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The scope of application of this Regulation should be clearly delimited from other Union harmonisation legislation concerning products, such as in vitro diagnostic medical devices, medicinal products, cosmetics and food. Therefore, Regulation\u00a0(EC)\u00a0No\u00a0178/2002 of the European Parliament and of the Council\u00a0(5) should be amended to exclude medical devices from its scope."}, "7": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "It should be the responsibility of the Member\u00a0States to decide on a case-by-case basis whether or not a product falls within the scope of this Regulation. In order to ensure consistent qualification decisions in that regard across all Member\u00a0States, particularly with regard to borderline cases, the Commission should be allowed to, on its own initiative or at the duly substantiated request of a Member\u00a0State, having consulted the Medical Device Coordination Group (\u2018MDCG\u2019), decide on a case-by-case basis whether or not a specific product, category or group of products falls within the scope of this Regulation. When deliberating on the regulatory status of products in borderline cases involving medicinal products, human tissues and cells, biocidal products or food products, the Commission should ensure an appropriate level of consultation of the European Medicines Agency\u00a0(EMA), the European Chemicals Agency and the European Food Safety Authority, as relevant."}, "8": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Since in some cases it is difficult to distinguish between medical devices and cosmetic products, the possibility of taking a Union-wide decision regarding the regulatory status of a product should also be introduced in Regulation\u00a0(EC)\u00a0No\u00a01223/2009 of the European Parliament and of the Council\u00a0(6)."}, "9": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Products which combine a medicinal product or substance and a medical device are regulated either under this Regulation or under Directive\u00a02001/83/EC of the European Parliament and of the Council.\u00a0(7) The two legislative acts should ensure appropriate interaction in terms of consultations during pre-market assessment, and of exchange of information in the context of vigilance activities involving such combination products. For medicinal products that integrate a medical device part, compliance with the general safety and performance requirements laid down in this Regulation for the device part should be adequately assessed in the context of the marketing authorisation for such medicinal products. Directive\u00a02001/83/EC should therefore be amended."}, "10": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Union legislation, in particular Regulation\u00a0(EC)\u00a0No\u00a01394/2007 of the European Parliament and of the Council\u00a0(8) and Directive\u00a02004/23/EC of the European Parliament and of the Council\u00a0(9), is incomplete in respect of certain products manufactured utilising derivatives of tissues or cells of human origin that are non-viable or are rendered non-viable. Such products should come under the scope of this Regulation, provided they comply with the definition of a medical device or are covered by this Regulation."}, "11": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Certain groups of products for which a manufacturer claims only an aesthetic or another non-medical purpose but which are similar to medical devices in terms of functioning and risks profile should be covered by this Regulation. In order for manufacturers to be able to demonstrate the conformity of such products, the Commission should adopt common specifications at least with regard to application of risk management and, where necessary, clinical evaluation regarding safety. Such common specifications should be developed specifically for a group of products without an intended medical purpose and should not be used for conformity assessment of the analogous devices with a medical purpose. Devices with both a medical and a non-medical intended purpose should fulfil both the requirements applicable to devices with, and to devices without, an intended medical purpose."}, "12": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "As is the case for products that contain viable tissues or cells of human or animal origin, that are explicitly excluded from Directives\u00a090/385/EEC and 93/42/EEC and hence from this Regulation, it should be clarified that products that contain or consist of viable biological materials or viable organisms of another origin in order to achieve or support the intended purpose of those products are not covered by this Regulation either."}, "13": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The requirements laid down in Directive\u00a02002/98/EC of the European Parliament and of the Council\u00a0(10) should continue to apply."}, "14": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "There is scientific uncertainty about the risks and benefits of nanomaterials used for devices. In order to ensure a high level of health protection, free movement of goods and legal certainty for manufacturers, it is necessary to introduce a uniform definition for nanomaterials based on Commission Recommendation\u00a02011/696/EU\u00a0(11), with the necessary flexibility to adapt that definition to scientific and technical progress and subsequent regulatory development at Union and international level. In the design and manufacture of devices, manufacturers should take special care when using nanoparticles for which there is a high or medium potential for internal exposure. Such devices should be subject to the most stringent conformity assessment procedures. In preparation of implementing acts regulating the practical and uniform application of the corresponding requirements laid down in this Regulation, the relevant scientific opinions of the relevant scientific committees should be taken into account."}, "15": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Safety aspects addressed by Directive\u00a02014/30/EU of the European Parliament and of the Council\u00a0(12) are an integral part of the general safety and performance requirements laid down in this Regulation for devices. Consequently, this Regulation should be considered a lex\u00a0specialis in relation to that Directive."}, "16": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "This Regulation should include requirements regarding the design and manufacture of devices emitting ionizing radiation without affecting the application of Council Directive\u00a02013/59/Euratom\u00a0(13) which pursues other objectives."}, "17": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "This Regulation should include requirements for devices' design, safety and performance characteristics which are developed in such a way as to prevent occupational injuries, including protection from radiation."}, "18": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "It is necessary to clarify that software in its own right, when specifically intended by the manufacturer to be used for one or more of the medical purposes set out in the definition of a medical device, qualifies as a medical device, while software for general purposes, even when used in a healthcare setting, or software intended for life-style and well-being purposes is not a medical device. The qualification of software, either as a device or an accessory, is independent of the software's location or the type of interconnection between the software and a device."}, "19": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The definitions in this Regulation, regarding devices themselves, the making available of devices, economic operators, users and specific processes, the conformity assessment, clinical investigations and clinical evaluations, post-market surveillance, vigilance and market surveillance, standards and other technical specifications, should be aligned with well-established practice in the field at Union and international level in order to enhance legal certainty."}, "20": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "It should be made clear that it is essential that devices offered to persons in the Union by means of information society services within the meaning of Directive\u00a0(EU)\u00a02015/1535 of the European Parliament and of the Council\u00a0(14) and devices used in the context of a commercial activity to provide a diagnostic or therapeutic service to persons within the Union comply with the requirements of this Regulation, where the product in question is placed on the market or the service is provided in the Union."}, "21": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "To recognise the important role of standardisation in the field of medical devices, compliance with harmonised standards as defined in Regulation (EU)\u00a0No\u00a01025/2012 of the European Parliament and of the Council\u00a0(15) should be a means for manufacturers to demonstrate conformity with the general safety and performance requirements and other legal requirements, such as those relating to quality and risk management, laid down in this Regulation."}, "22": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Directive\u00a098/79/EC of the European Parliament and of the Council\u00a0(16) allows the Commission to adopt common technical specifications for specific categories of in vitro diagnostic medical devices. In areas where no harmonised standards exist or where they are insufficient, the Commission should be empowered to lay down common specifications which provide a means of complying with the general safety and performance requirements, and the requirements for clinical investigations and clinical evaluation and/or post-market clinical follow-up, laid down in this Regulation."}, "23": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Common specifications (\u2018CS\u2019) should be developed after consulting the relevant stakeholders and taking account of European and international standards."}, "24": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The rules applicable to devices should be aligned, where appropriate, with the New Legislative Framework for the Marketing of Products, which consists of Regulation\u00a0(EC)\u00a0No\u00a0765/2008 of the European Parliament and of the Council\u00a0(17) and Decision\u00a0No\u00a0768/2008/EC of the European Parliament and of the Council\u00a0(18)."}, "25": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The rules on Union market surveillance and control of products entering the Union market laid down in Regulation\u00a0(EC)\u00a0No\u00a0765/2008 apply to devices covered by this Regulation which does not prevent Member\u00a0States from choosing the competent authorities to carry out those tasks."}, "26": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "It is appropriate to set out clearly the general obligations of the different economic operators, including importers and distributors, building on the New Legislative Framework for the Marketing of Products, without prejudice to the specific obligations laid down in the various parts of this Regulation, to enhance understanding of the requirements laid down in this Regulation and thus to improve regulatory compliance by the relevant operators."}, "27": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "For the purpose of this Regulation, the activities of distributors should be deemed to include acquisition, holding and supplying of devices."}, "28": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Several of the obligations on manufacturers, such as clinical evaluation or vigilance reporting, that were set out only in the Annexes\u00a0to Directives\u00a090/385/EEC and\u00a093/42/EEC, should be incorporated into the enacting provisions of this Regulation to facilitate its application."}, "29": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Health institutions should have the possibility of manufacturing, modifying and using devices in-house and thereby address, on a non-industrial scale, the specific needs of target patient groups which cannot be met at the appropriate level of performance by an equivalent device available on the market. In that context, it is appropriate to provide that certain rules of this Regulation, as regards medical devices manufactured and used only within health institutions, including hospitals as well as institutions, such as laboratories and public health institutes that support the healthcare system and/or address patient needs, but which do not treat or care for patients directly, should not apply, since the aims of this Regulation would still be met in a proportionate manner. It should be noted that the concept of \u2018health institution\u2019 does not cover establishments primarily claiming to pursue health interests or healthy lifestyles, such as gyms, spas, wellness and fitness centres. As a result, the exemption applicable to health institutions does not apply to such establishments."}, "30": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "In view of the fact that natural or legal persons can claim compensation for damage caused by a defective device in accordance with applicable Union and national law, it is appropriate to require manufacturers to have measures in place to provide sufficient financial coverage in respect of their potential liability under Council Directive\u00a085/374/EEC\u00a0(19). Such measures should be proportionate to the risk class, type of device and the size of the enterprise. In this context, it is also appropriate to lay down rules concerning the facilitation, by a competent authority, of the provision of information to persons who may have been injured by a defective device."}, "31": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "To ensure that devices manufactured in series production continue to be in conformity with the requirements of this Regulation and that experience from the use of the devices they manufacture is taken into account for the production process, all manufacturers should have a quality management system and a post-market surveillance system in place which should be proportionate to the risk class and the type of the device in question. In addition, in order to minimize risks or prevent incidents related to devices, manufacturers should establish a system for risk management and a system for reporting of incidents and field safety corrective actions."}, "32": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The risk management system should be carefully aligned with and reflected in the clinical evaluation for the device, including the clinical risks to be addressed as part of clinical investigations, clinical evaluation and post-market clinical follow up. The risk management and clinical evaluation processes should be inter-dependent and should be regularly updated."}, "33": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "It should be ensured that supervision and control of the manufacture of devices, and the post-market surveillance and vigilance activities concerning them, are carried out within the manufacturer's organisation by a person responsible for regulatory compliance who fulfils minimum conditions of qualification."}, "34": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "For manufacturers who are not established in the Union, the authorised representative plays a pivotal role in ensuring the compliance of the devices produced by those manufacturers and in serving as their contact person established in the Union. Given that pivotal role, for the purposes of enforcement it is appropriate to make the authorised representative legally liable for defective devices in the event that a manufacturer established outside the Union has not complied with its general obligations. The liability of the authorised representative provided for in this Regulation is without prejudice to the provisions of Directive\u00a085/374/EEC, and accordingly the authorised representative should be jointly and severally liable with the importer and the manufacturer. The tasks of an authorised representative should be defined in a written mandate. Considering the role of authorised representatives, the minimum requirements they should meet should be clearly defined, including the requirement of having available a person who fulfils minimum conditions of qualification which should be similar to those for a manufacturer's person responsible for regulatory compliance."}, "35": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "To ensure legal certainty in respect of the obligations incumbent on economic operators, it is necessary to clarify when a distributor, importer or other person is to be considered the manufacturer of a device."}, "36": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Parallel trade in products already placed on the market is a lawful form of trade within the internal market on the basis of Article\u00a034 TFEU subject to the limitations arising from the need for protection of health and safety and from the need for protection of intellectual property rights provided for under Article\u00a036 TFEU. Application of the principle of parallel trade is, however, subject to different interpretations in the Member\u00a0States. The conditions, in particular the requirements for relabelling and repackaging, should therefore be specified in this Regulation, taking into account the case-law of the Court of Justice\u00a0(20) in other relevant sectors and existing good practice in the field of medical devices."}, "37": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The reprocessing and further use of single-use devices should only take place where permitted by national law and while complying with the requirements laid down in this Regulation. The reprocessor of a single-use device should be considered to be the manufacturer of the reprocessed device and should assume the obligations incumbent on manufacturers under this Regulation. Nevertheless, Member\u00a0States should have the possibility of deciding that the obligations relating to reprocessing and re-use of single-use devices within a health institution or by an external reprocessor acting on its behalf may differ from the obligations on a manufacturer described in this Regulation. In principle, such divergence should only be permitted where reprocessing and reuse of single-use devices within a health institution or by an external reprocessor are compliant with CS that have been adopted, or, in the absence of such CS, with relevant harmonised standards and national provisions. The reprocessing of such devices should ensure an equivalent level of safety and performance to that of the corresponding initial single-use device."}, "38": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Patients who are implanted with a device should be given clear and easily accessible essential information allowing the implanted device to be identified and other relevant information about the device, including any necessary health risk warnings or precautions to be taken, for example indications as to whether or not it is compatible with certain diagnostic devices or with scanners used for security controls."}, "39": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Devices should, as a general rule, bear the CE marking to indicate their conformity with this Regulation so that they can move freely within the Union and be put into service in accordance with their intended purpose. Member\u00a0States should not create obstacles to the placing on the market or putting into service of devices that comply with the requirements laid down in this Regulation. However, Member\u00a0States should be allowed to decide whether to restrict the use of any specific type of device in relation to aspects that are not covered by this Regulation."}, "40": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The traceability of devices by means of a Unique Device Identification system\u00a0(UDI\u00a0system) based on international guidance should significantly enhance the effectiveness of the post-market safety-related activities for devices, which is owing to improved incident reporting, targeted field safety corrective actions and better monitoring by competent authorities. It should also help to reduce medical errors and to fight against falsified devices. Use of the UDI system should also improve purchasing and waste disposal policies and stock-management by health institutions and other economic operators and, where possible, be compatible with other authentication systems already in place in those settings."}, "41": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The UDI system should apply to all devices placed on the market except custom-made devices, and be based on internationally recognised principles including definitions that are compatible with those used by major trade partners. In order for the UDI system to become functional in time for the application of this Regulation, detailed rules should be laid down in this Regulation."}, "42": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Transparency and adequate access to information, appropriately presented for the intended user, are essential in the public interest, to protect public health, to empower patients and healthcare professionals and to enable them to make informed decisions, to provide a sound basis for regulatory decision-making and to build confidence in the regulatory system."}, "43": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "One key aspect in fulfilling the objectives of this Regulation is the creation of a European database on medical devices (Eudamed) that should integrate different electronic systems to collate and process information regarding devices on the market and the relevant economic operators, certain aspects of conformity assessment, notified bodies, certificates, clinical investigations, vigilance and market surveillance. The objectives of the database are to enhance overall transparency, including through better access to information for the public and healthcare professionals, to avoid multiple reporting requirements, to enhance coordination between Member\u00a0States and to streamline and facilitate the flow of information between economic operators, notified bodies or sponsors and Member\u00a0States as well as between Member\u00a0States among themselves and with the Commission. Within the internal market, this can be ensured effectively only at Union level and the Commission should therefore further\u00a0develop and manage the European databank on medical devices set up by Commission Decision\u00a02010/227/EU\u00a0(21)."}, "44": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "To facilitate the functioning of Eudamed, an internationally recognised medical device nomenclature should be available free of charge to manufacturers and other natural or legal persons required by this Regulation to use that nomenclature. Furthermore, that nomenclature should be available, where reasonably practicable, free of charge also to other stakeholders."}, "45": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Eudamed's electronic systems regarding devices on the market, the relevant economic operators and certificates should enable the public to be adequately informed about devices on the Union market. The electronic system on clinical investigations should serve as a tool for the cooperation between Member\u00a0States and for enabling sponsors to submit, on a voluntary basis, a single application for several Member\u00a0States and to report serious adverse events, device deficiencies and related updates. The electronic system on vigilance should enable manufacturers to report serious incidents and other reportable events and to support the coordination of the evaluation of such incidents and events by competent authorities. The electronic system regarding market surveillance should be a tool for the exchange of information between competent authorities."}, "46": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "In respect of data collated and processed through the electronic systems of Eudamed, Directive\u00a095/46/EC of the European Parliament and of the Council\u00a0(22) applies to the processing of personal data carried out in the Member\u00a0States, under the supervision of the Member\u00a0States' competent authorities, in particular the public independent authorities designated by the Member\u00a0States. Regulation\u00a0(EC)\u00a0No\u00a045/2001 of the European Parliament and of the Council\u00a0(23) applies to the processing of personal data carried out by the Commission within the framework of this Regulation, under the supervision of the European Data Protection Supervisor. In accordance with Regulation\u00a0(EC)\u00a0No\u00a045/2001, the Commission should be designated as the controller of Eudamed and its electronic systems."}, "47": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "For implantable devices and for class III devices, manufacturers should summarise the main safety and performance aspects of the device and the outcome of the clinical evaluation in a document that should be publicly available."}, "48": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The summary of safety and clinical performance for a device should include in particular the place of the device in the context of diagnostic or therapeutic options taking into account the clinical evaluation of that device when compared to the diagnostic or therapeutic alternatives and the specific conditions under which that device and its alternatives can be considered."}, "49": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The proper functioning of notified bodies is crucial for ensuring a high level of health and safety protection and citizens' confidence in the system. Designation and monitoring of notified bodies by the Member\u00a0States, in accordance with detailed and strict criteria, should therefore be subject to controls at Union level."}, "50": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Notified bodies' assessments of manufacturers' technical documentation, in particular documentation on clinical evaluation, should be critically evaluated by the authority responsible for notified bodies. That evaluation should be part of the risk-based approach to the oversight and monitoring activities of notified bodies and should be based on sampling of the relevant documentation."}, "51": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The position of notified bodies vis-\u00e0-vis manufacturers should be strengthened, including with regard to their right and duty to carry out unannounced on-site audits and to conduct physical or laboratory tests on devices to ensure continuous compliance by manufacturers after receipt of the original certification."}, "52": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "To increase transparency with regard to the oversight of notified bodies by national authorities, the authorities responsible for notified bodies should publish information on the national measures governing the assessment, designation and monitoring of notified bodies. In accordance with good administrative practice, this information should be kept up to date by those authorities in particular to reflect relevant, significant or substantive changes to the procedures in question."}, "53": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The Member\u00a0State in which a notified body is established should be responsible for enforcing the requirements of this Regulation with regard to that notified body."}, "54": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "In view, in particular, of the responsibility of Member\u00a0States for the organisation and delivery of health services and medical care, they should be allowed to lay down additional requirements on notified bodies designated for the conformity assessment of devices and established on their territory as far as issues that are not regulated in this Regulation are concerned. Any such additional requirements laid down should not affect more specific horizontal Union legislation on notified bodies and equal treatment of notified bodies."}, "55": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "For class III implantable devices and class IIb active devices intended to administer and/or remove a medicinal product, notified bodies should, except in certain cases, be obliged to request expert panels to scrutinise their clinical evaluation assessment report. Competent authorities should be informed about devices that have been granted a certificate following a conformity assessment procedure involving an expert panel. The consultation of expert panels in relation to the clinical evaluation should lead to a harmonised evaluation of high-risk medical devices by sharing expertise on clinical aspects and developing CS on categories of devices that have undergone that consultation process."}, "56": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "For class\u00a0III devices and for certain class\u00a0IIb devices, a manufacturer should be able to consult voluntarily an expert panel, prior to that manufacturer's clinical evaluation and/or investigation, on its clinical development strategy and on proposals for clinical investigations."}, "57": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "It is necessary, in particular for the purpose of the conformity assessment procedures, to maintain the division of devices into four product classes in line with international practice. The classification rules, which are based on the vulnerability of the human body, should take into account the potential risks associated with the technical design and manufacture of the devices. To maintain the same level of safety as provided by Directive\u00a090/385/EEC, active implantable devices should be in the highest risk class."}, "58": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Rules under the old regime applied to invasive devices do not sufficiently take account of the level of invasiveness and potential toxicity of certain devices which are introduced into the human body. In order to obtain a suitable risk-based classification of devices that are composed of substances or of combinations of substances that are absorbed by or locally dispersed in the human body, it is necessary to introduce specific classification rules for such devices. The classification rules should take into account the place where the device performs its action in or on the human body, where it is introduced or applied, and whether a systemic absorption of the substances of which the device is composed, or of the products of metabolism in the human body of those substances occurs."}, "59": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The conformity assessment procedure for class I devices should be carried out, as a general rule, under the sole responsibility of manufacturers in view of the low level of vulnerability associated with such devices. For class\u00a0IIa, class\u00a0IIb and class\u00a0III devices, an appropriate level of involvement of a notified body should be compulsory."}, "60": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The conformity assessment procedures for devices should be further strengthened and streamlined whilst the requirements for notified bodies as regards the performance of their assessments should be clearly specified to ensure a level playing field."}, "61": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "It is appropriate that certificates of free sale contain information that makes it possible to use Eudamed in order to obtain information on the device, in particular with regard to whether it is on the market, withdrawn from the market or recalled, and on any certificate on its conformity."}, "62": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "To ensure a high level of safety and performance, demonstration of compliance with the general safety and performance requirements laid down in this Regulation should be based on clinical data that, for class\u00a0III\u00a0devices and implantable devices should, as a general rule, be sourced from clinical investigations that have been carried out under the responsibility of a sponsor. It should be possible both for the manufacturer and for another natural or legal person to be the sponsor taking responsibility for the clinical investigation."}, "63": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The rules on clinical investigations should be in line with well-established international guidance in this field, such as the international standard ISO\u00a014155:2011 on good clinical practice for clinical investigations of medical devices for human subjects, so as to make it easier for the results of clinical investigations conducted in the Union to be accepted as documentation outside the Union and to make it easier for the results of clinical investigations conducted outside the Union in accordance with international guidelines to be accepted within the Union. In addition, the rules should be in line with the most recent version of the World Medical Association Declaration of Helsinki on Ethical Principles for Medical Research Involving Human Subjects."}, "64": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "It should be left to the Member\u00a0State where a clinical investigation is to be conducted to determine the appropriate authority to be involved in the assessment of the application to conduct a clinical investigation and to organise the involvement of ethics committees within the timelines for the authorisation of that clinical investigation as set out in this Regulation. Such decisions are a matter of internal organisation for each Member\u00a0State. In that context, Member\u00a0States should ensure the involvement of laypersons, in particular patients or patients' organisations. They should also ensure that the necessary expertise is available."}, "65": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Where, in the course of a clinical investigation, harm caused to a subject leads to the civil or criminal liability of the investigator or the sponsor being invoked, the conditions for liability in such cases, including issues of causality and the level of damages and sanctions, should remain governed by national law."}, "66": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "An electronic system should be set up at Union level to ensure that every clinical investigation is recorded and reported in a publicly accessible database. To protect the right to the protection of personal data, recognised by Article\u00a08 of the Charter of Fundamental Rights of the European Union (\u2018the Charter\u2019), no personal data of subjects participating in a clinical investigation should be recorded in the electronic system. To ensure synergies with the area of clinical trials on medicinal products, the electronic system on clinical investigations should be interoperable with the EU database to be set up for clinical trials on medicinal products for human use."}, "67": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Where a clinical investigation is to be conducted in more than one Member\u00a0State, the sponsor should have the possibility of submitting a single application in order to reduce administrative burden. In order to allow for resource-sharing and to ensure consistency regarding the assessment of the health and safety-related aspects of the investigational device and of the scientific design of that clinical investigation, the procedure for the assessment of such single application should be coordinated between the Member\u00a0States under the direction of a coordinating Member\u00a0State. Such coordinated assessment should not include the assessment of intrinsically national, local and ethical aspects of a clinical investigation, including informed consent. For an initial period of seven years from the date of application of this Regulation, Member\u00a0States should be able to participate on a voluntary basis in the coordinated assessment. After that period, all Member\u00a0States should be obliged to participate in the coordinated assessment. The Commission, based on the experience gained from the voluntary coordination between Member\u00a0States, should draw up a report on the application of the relevant provisions regarding the coordinated assessment procedure. In the event that the findings of the report are negative, the Commission should submit a proposal to extend the period of participation on a voluntary basis in the coordinated assessment procedure."}, "68": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Sponsors should report certain adverse events and device deficiencies that occur during clinical investigations to the Member\u00a0States in which those clinical investigations are being conducted. Member\u00a0States should have the possibility of terminating or suspending the investigations or revoking the authorisation for those investigations, if considered necessary to ensure a high level of protection of the subjects participating in a clinical investigation. Such information should be communicated to the other Member\u00a0States."}, "69": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The sponsor of a clinical investigation should submit a summary of results of the clinical investigation that is easily understandable for the intended user together with the clinical investigation report, where applicable, within the timelines laid down in this Regulation. Where it is not possible to submit the summary of the results within the defined timelines for scientific reasons, the sponsor should justify this and specify when the results will be submitted."}, "70": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "This Regulation should cover clinical investigations intended to gather clinical evidence for the purpose of demonstrating conformity of devices and should also lay down basic requirements regarding ethical and scientific assessments for other types of clinical investigations of medical devices."}, "71": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Incapacitated subjects, minors, pregnant women and breastfeeding women require specific protection measures. However, it should be left to Member\u00a0States to determine the legally designated representatives of incapacitated subjects and minors."}, "72": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The principles of replacement, reduction and refinement in the area of animal experimentation laid down in the Directive\u00a02010/63/EU of the European Parliament and of the Council\u00a0(24) should be observed. In particular, the unnecessary duplication of tests and studies should be avoided."}, "73": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Manufacturers should play an active role during the post-market phase by systematically and actively gathering information from post-market experience with their devices in order to update their technical documentation and cooperate with the national competent authorities in charge of vigilance and market surveillance activities. To this end, manufacturers should establish a comprehensive post-market surveillance system, set up under their quality management system and based on a post-market surveillance plan. Relevant data and information gathered through post-market surveillance, as well as lessons learned from any implemented preventive and/or corrective actions, should be used to update any relevant part of technical documentation, such as those relating to risk assessment and clinical evaluation, and should also serve the purpose of transparency."}, "74": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "In order to better protect health and safety regarding devices on the market, the electronic system on vigilance for devices should be made more effective by creating a central portal at Union level for reporting serious incidents and field safety corrective actions."}, "75": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Member\u00a0States should take appropriate measures to raise awareness among healthcare professionals, users and patients about the importance of reporting incidents. Healthcare professionals, users and patients should be encouraged and enabled to report suspected serious incidents at national level using harmonised formats. The national competent authorities should inform manufacturers of any suspected serious incidents and, where a manufacturer confirms that such an incident has occurred, the authorities concerned should ensure that appropriate follow-up action is taken in order to minimise recurrence of such incidents."}, "76": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The evaluation of reported serious incidents and field safety corrective actions should be conducted at national level but coordination should be ensured where similar incidents have occurred or field safety corrective actions have to be carried out in more than one Member\u00a0State, with the objective of sharing resources and ensuring consistency regarding the corrective action."}, "77": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "In the context of the investigation of incidents, the competent authorities should take into account, where appropriate, the information provided by and views of relevant stakeholders, including patient and healthcare professionals' organisations and manufacturers' associations."}, "78": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The reporting of serious adverse events or device deficiencies during clinical investigations and the reporting of serious incidents occurring after a device has been placed on the market should be clearly distinguished to avoid double reporting."}, "79": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Rules on market surveillance should be included in this Regulation to reinforce the rights and obligations of the national competent authorities, to ensure effective coordination of their market surveillance activities and to clarify the applicable procedures."}, "80": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Any statistically significant increase in the number or severity of incidents that are not serious or in expected side-effects that could have a significant impact on the benefit-risk analysis and which could lead to unacceptable risks should be reported to the competent authorities in order to permit their assessment and the adoption of appropriate measures."}, "81": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "An expert committee, the Medical Device Coordination Group (MDCG), composed of persons designated by the Member\u00a0States based on their role and expertise in the field of medical devices including in vitro diagnostic medical devices, should be established to fulfil the tasks conferred on it by this Regulation and by Regulation\u00a0(EU)\u00a02017/746 of the European Parliament and of the Council\u00a0(25), to provide advice to the Commission and to assist the Commission and the Member\u00a0States in ensuring a harmonised implementation of this Regulation. The MDCG should be able to establish subgroups in order to have access to necessary in-depth technical expertise in the field of medical devices including in vitro diagnostic medical devices. When establishing subgroups, appropriate consideration should be given to the possibility of involving existing groups at Union level in the field of medical devices."}, "82": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Expert panels and expert laboratories should be designated by the Commission on the basis of their up-to-date clinical, scientific or technical expertise, with the aim of providing scientific, technical and clinical assistance to the Commission, the MDCG, manufacturers and notified bodies in relation to the implementation of this Regulation. Moreover, expert panels should fulfil the tasks of providing an opinion on clinical evaluation assessment reports of notified bodies in the case of certain high-risk devices."}, "83": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Closer coordination between national competent authorities through information exchange and coordinated assessments under the direction of a coordinating authority is essential for ensuring a consistently high level of health and safety protection within the internal market, in particular in the areas of clinical investigations and vigilance. The principle of coordinated exchange and assessment should also apply across other authority activities described in this Regulation, such as the designation of notified bodies and should be encouraged in the area of market surveillance of devices. Joint working, coordination and communication of activities should also lead to more efficient use of resources and expertise at national level."}, "84": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The Commission should provide scientific, technical and corresponding logistical support to coordinating national authorities and ensure that the regulatory system for devices is effectively and uniformly implemented at Union level based on sound scientific evidence."}, "85": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The Union and, where appropriate, the Member\u00a0States should actively participate in international regulatory cooperation in the field of medical devices to facilitate the exchange of safety-related information regarding medical devices and to foster the further development of international regulatory guidelines that promote the adoption in other jurisdictions of regulations that lead to a level of health and safety protection equivalent to that set by this Regulation."}, "86": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Member\u00a0States should take all necessary measures to ensure that the provisions of this Regulation are implemented, including by laying down effective, proportionate and dissuasive penalties for their infringement."}, "87": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Whilst this Regulation should not affect the right of Member\u00a0States to levy fees for activities at national level, Member\u00a0States should, in order to ensure transparency, inform the Commission and the other Member\u00a0States before they decide on the level and structure of such fees. In order to further ensure transparency, the structure and level of the fees should be publicly available on request."}, "88": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "This Regulation respects the fundamental rights and observes the principles recognised in particular by the Charter and in particular human dignity, the integrity of the person, the protection of personal data, the freedom of art and science, the freedom to conduct business and the right to property. This Regulation should be applied by the Member\u00a0States in accordance with those rights and principles."}, "89": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The power to adopt delegated acts in accordance with Article\u00a0290 TFEU should be delegated to the Commission in order to amend certain non-essential provisions of this Regulation. It is of particular importance that the Commission carry out appropriate consultations during its preparatory work, including at expert level, and that those consultations be conducted in accordance with the principles laid down in the Interinstitutional Agreement of 13\u00a0April\u00a02016 on Better Law-Making\u00a0(26). In particular, to ensure equal participation in the preparation of delegated acts, the European Parliament and the Council receive all documents at the same time as Member\u00a0States' experts, and their experts systematically have access to meetings of Commission expert groups dealing with preparation of delegated acts."}, "90": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "In order to ensure uniform conditions for the implementation of this Regulation, implementing powers should\u00a0be conferred on the Commission. Those powers should be exercised in accordance with Regulation\u00a0(EU)\u00a0No\u00a0182/2011 of the European Parliament and of the Council\u00a0(27)."}, "91": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The advisory procedure should be used for implementing acts that set out the form and presentation of the data elements of manufacturers' summaries of safety and clinical performance, and that establish the model for certificates of free sale, given that such implementing acts are of a procedural nature and do not directly have an impact on health and safety at Union level."}, "92": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The Commission should adopt immediately applicable implementing acts where, in duly justified cases relating to the extension to the territory of the Union of a national derogation from the applicable conformity assessment procedures, imperative grounds of urgency so require."}, "93": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "In order to enable it to designate issuing entities, expert panels and expert laboratories, implementing powers should be conferred on the Commission."}, "94": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "To allow economic operators, especially SMEs, notified bodies, Member\u00a0States and the Commission to adapt to the changes introduced by this Regulation and to ensure its proper application, it is appropriate to provide for a sufficient transitional period for that adaptation and for the organisational arrangements that are to be made. However, certain parts of the Regulation that directly affect Member\u00a0States and the Commission should be implemented as soon as possible. It is also particularly important that, by the date of application of this Regulation, a sufficient number of notified bodies be designated in accordance with the new requirements so as to avoid any shortage of medical devices on the market. Nonetheless, it is necessary that any designation of a notified body in accordance with the requirements of this Regulation prior to the date of its application be without prejudice to the validity of the designation of those notified bodies under Directives\u00a090/385/EEC and 93/42/EEC and to their capacity to continue issuing valid certificates under those two Directives until the date of application of this Regulation."}, "95": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "In order to ensure a smooth transition to the new rules for registration of devices and of certificates, the obligation to submit the relevant information to the electronic systems set up at Union level pursuant to this Regulation should, in the event that the corresponding IT\u00a0systems are developed according to plan, only become fully effective from 18\u00a0months after the date of application of this Regulation. During this transitional period, certain provisions of Directives\u00a090/385/EEC and 93/42/EEC should remain in force. However, in order to avoid multiple registrations, economic operators and notified bodies who register in the relevant electronic systems set up at Union level pursuant to this Regulation should be considered to be in compliance with the registration requirements adopted by the Member\u00a0States pursuant to those provisions."}, "96": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "In order to provide for a smooth introduction of the UDI system, the moment of application of the obligation to place the UDI carrier on the label of the device should vary from one to five years after the date of application of this Regulation depending upon the class of the device concerned."}, "97": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Directives\u00a090/385/EEC and 93/42/EEC should be repealed to ensure that only one set of rules applies to the placing of medical devices on the market and the related aspects covered by this Regulation. Manufacturers' obligations as regards the making available of documentation regarding devices they placed on the market and manufacturers' and Member\u00a0States' obligations as regards vigilance activities for devices placed on the market pursuant to those Directives should however continue to apply. While it should be left to Member\u00a0States to decide how to organise vigilance activities, it is desirable for them to have the possibility of reporting incidents related to devices placed on the market pursuant to the Directives using the same tools as those for reporting on devices placed on the market pursuant to this Regulation. It is furthermore appropriate, in order to ensure a smooth transition from the old regime to the new regime, to provide that Commission Regulation\u00a0(EU)\u00a0No\u00a0207/2012\u00a0(28) and Commission Regulation\u00a0(EU)\u00a0No\u00a0722/2012\u00a0(29) should remain in force and continue to apply unless and until repealed by implementing acts adopted by the Commission pursuant to this Regulation.Decision\u00a02010/227/EU adopted in implementation of those Directives and Directive\u00a098/79/EC should also remain in force and continue to apply until the date when Eudamed becomes fully functional. Conversely, no such maintenance in force is required for Commission Directives\u00a02003/12/EC\u00a0(30) and 2005/50/EC\u00a0(31) and Commission Implementing Regulation (EU)\u00a0No\u00a0920/2013\u00a0(32)."}, "98": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The requirements of this Regulation should be applicable to all devices placed on the market or put into service from the date of application of this Regulation. However, in order to provide for a smooth transition it should be possible, for a limited period of time from that date, for devices to be placed on the market or put into service by virtue of a valid certificate issued pursuant to Directive\u00a090/385/EEC or pursuant to Directive\u00a093/42/EEC."}, "99": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "The European Data Protection Supervisor has given an opinion\u00a0(33) pursuant to Article\u00a028(2) of\u00a0Regulation\u00a0(EC)\u00a0No\u00a045/2001."}, "100": {"chapter": "about the medical device regulation", "article": "aims of the document", "definition": "Since the objectives of this Regulation, namely to ensure the smooth functioning of the internal market as regards medical devices and to ensure high standards of quality and safety for medical devices, thus ensuring a high level of protection of health and safety of patients, users and other persons, cannot be sufficiently achieved by the Member\u00a0States but can rather, by reason of its scale and effects, be better achieved at Union level, the Union may adopt measures, in accordance with the principle of subsidiarity as set out in Article\u00a05 of the Treaty on European Union. In accordance with the principle of proportionality, as set out in that Article, this Regulation does not go beyond what is necessary in order to achieve those objectives,"}, "101": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "This Regulation lays down rules concerning the placing on the market, making available on the market or putting into service of medical devices for human use and accessories for such devices in the Union. This Regulation also applies to clinical investigations concerning such medical devices and accessories conducted in the Union."}, "102": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "This Regulation shall also apply, as from the date of application of common specifications adopted pursuant to Article\u00a09, to the groups of products without an intended medical purpose that are listed in Annex\u00a0XVI, taking into account the state of the art, and in particular existing harmonised standards for analogous devices with a medical purpose, based on similar technology. The common specifications for each of the groups of products listed in Annex\u00a0XVI shall address, at least, application of risk management as set out in Annex\u00a0I for the group of products in question and, where necessary, clinical evaluation regarding safety.The necessary common specifications shall be adopted by 26 May 2020. They shall apply as from six months after the date of their entry into force or from 26 May 2020, whichever is the latest.Notwithstanding Article\u00a0122, Member\u00a0States' measures regarding the qualification of the products covered by Annex\u00a0XVI as medical devices pursuant to Directive\u00a093/42/EEC shall remain valid until the date of application, as referred to in the first subparagraph, of the relevant common specifications for that group of products.This Regulation also applies to clinical investigations conducted in the Union concerning the products referred to in the first subparagraph."}, "103": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "Devices with both a medical and a non-medical intended purpose shall fulfil cumulatively the requirements applicable to devices with an intended medical purpose and those applicable to devices without an intended medical purpose."}, "104": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "For the purposes of this Regulation, medical devices, accessories for medical devices, and products listed in Annex\u00a0XVI to which this Regulation applies pursuant to paragraph\u00a02 shall hereinafter be referred to as \u2018devices\u2019."}, "105": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "Where justified on account of the similarity between a device with an intended medical purpose placed on the market and a product without an intended medical purpose in respect of their characteristics and risks, the Commission is empowered to adopt delegated acts in accordance with Article\u00a0115 to amend the list in Annex\u00a0XVI, by adding new groups of products, in order to protect the health and safety of users or other persons or other aspects of public health."}, "106": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "This Regulation does not apply to: \nin vitro diagnostic medical devices covered by Regulation\u00a0(EU)\u00a02017/746;"}, "107": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "This Regulation does not apply to: medicinal products as defined in point\u00a02 of Article\u00a01 of Directive\u00a02001/83/EC. In deciding whether a product falls under Directive\u00a02001/83/EC or under this Regulation, particular account shall be taken of the principal mode of action of the product;"}, "108": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "This Regulation does not apply to: advanced therapy medicinal products covered by Regulation\u00a0(EC)\u00a0No\u00a01394/2007;"}, "109": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "This Regulation does not apply to: human blood, blood products, plasma or blood cells of human origin or devices which incorporate, when placed on the market or put into service, such blood products, plasma or cells, except for devices referred to in paragraph\u00a08 of this Article;"}, "110": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "This Regulation does not apply to: cosmetic products covered by Regulation\u00a0(EC)\u00a0No\u00a01223/2009;"}, "111": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "This Regulation does not apply to: transplants, tissues or cells of animal origin, or their derivatives, or products containing or consisting of them; however this Regulation does apply to devices manufactured utilising tissues or cells of animal origin, or their derivatives, which are non-viable or are rendered non-viable;"}, "112": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "This Regulation does not apply to: transplants, tissues or cells of human origin, or their derivatives, covered by Directive\u00a02004/23/EC, or products containing or consisting of them; however this Regulation does apply to devices manufactured utilising derivatives of tissues or cells of human origin which are non-viable or are rendered non-viable;"}, "113": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "This Regulation does not apply to: products, other than those referred to in points (d), (f) and (g), that contain or consist of viable biological material or viable organisms, including living micro-organisms, bacteria, fungi or viruses in order to achieve or support the intended purpose of the product;"}, "114": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "This Regulation does not apply to: food covered by Regulation (EC)\u00a0No\u00a0178/2002."}, "115": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "Any device which, when placed on the market or put into service, incorporates as an integral part an in vitro diagnostic medical device as defined in point\u00a02 of Article\u00a02 of Regulation\u00a0(EU)\u00a02017/746, shall be governed by this Regulation. The requirements of Regulation\u00a0(EU)\u00a02017/746 shall apply to the in vitro diagnostic medical device part of the device."}, "116": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "Any device which, when placed on the market or put into service, incorporates, as an integral part, a substance which, if used separately, would be considered to be a medicinal product as defined in point\u00a02 of Article\u00a01 of Directive\u00a02001/83/EC, including a medicinal product derived from human blood or human plasma as defined in point\u00a010 of Article\u00a01 of that Directive, and that has an action ancillary to that of the device, shall be assessed and authorised in accordance with this Regulation.However, if the action of that substance is principal and not ancillary to that of the device, the integral product shall be governed by Directive\u00a02001/83/EC or Regulation\u00a0(EC)\u00a0No\u00a0726/2004 of the European Parliament and of the Council\u00a0(34), as applicable. In that case, the relevant general safety and performance requirements set out in Annex\u00a0I to this Regulation shall apply as far as the safety and performance of the device part are concerned."}, "117": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "Any device which is intended to administer a medicinal product as defined in point\u00a02 of Article\u00a01 of Directive\u00a02001/83/EC shall be governed by this Regulation, without prejudice to the provisions of that Directive\u00a0and of Regulation\u00a0(EC)\u00a0No\u00a0726/2004 with regard to the medicinal product.However, if the device intended to administer a medicinal product and the medicinal product are placed on the market in such a way that they form a single integral product which is intended exclusively for use in the given combination and which is not reusable, that single integral product shall be governed by Directive\u00a02001/83/EC or Regulation\u00a0(EC)\u00a0No\u00a0726/2004, as applicable. In that case, the relevant general safety and performance requirements set out in Annex\u00a0I to this Regulation shall apply as far as the safety and performance of the device part of the single integral product are concerned."}, "118": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "\u00a0Any device which, when placed on the market or put into service, incorporates, as an integral part, non-viable tissues or cells of human origin or their derivatives that have an action ancillary to that of the device shall be assessed and authorised in accordance with this Regulation. In that case, the provisions for donation, procurement and testing laid down in Directive\u00a02004/23/EC shall apply.However, if the action of those tissues or cells or their derivatives is principal and not ancillary to that of the device and the product is not governed by Regulation\u00a0(EC)\u00a0No\u00a01394/2007, the product shall be governed by Directive\u00a02004/23/EC. In that case, the relevant general safety and performance requirements set out in Annex\u00a0I to this Regulation shall apply as far as the safety and performance of the device part are concerned."}, "119": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "This Regulation is specific Union legislation within the meaning of Article\u00a02(3) of Directive\u00a02014/30/EU.12.\u00a0\u00a0\u00a0Devices that are also machinery within the meaning of point\u00a0(a) of the second paragraph\u00a0of Article\u00a02 of Directive\u00a02006/42/EC of the European Parliament and of the Council\u00a0(35) shall, where a hazard relevant under that Directive\u00a0exists, also meet the essential health and safety requirements set out in Annex\u00a0I to that Directive\u00a0to the extent to which those requirements are more specific than the general safety and performance requirements set out in Chapter\u00a0II of Annex\u00a0I to this Regulation."}, "120": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "This Regulation shall not affect the application of Directive\u00a02013/59/Euratom."}, "121": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "This Regulation shall not affect the right of a Member\u00a0State to restrict the use of any specific type of device in relation to aspects not covered by this Regulation."}, "122": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "This Regulation shall not affect national law concerning the organisation, delivery or financing of health services and medical care, such as the requirement that certain devices may only be supplied on a medical prescription, the requirement that only certain health professionals or healthcare institutions may dispense or use certain devices or that their use be accompanied by specific professional counselling."}, "123": {"chapter": "\nSCOPE AND DEFINITIONS\n", "article": "Subject matter and scope", "definition": "Nothing in this Regulation shall restrict the freedom of the press or the freedom of expression in the media in so far as those freedoms are guaranteed in the Union and in the Member\u00a0States, in particular under Article\u00a011 of the Charter of Fundamental Rights of the European Union."}}